Process and kit for determining in vitro the immune status of an individual

Patent metadata

Field	Value
Publication number	US-9982298-B2
Application number	US-201213978827-A
Country	US
Kind code	B2
Filing date	Jan 27, 2012
Priority date	Jan 27, 2011
Publication date	May 29, 2018
Grant date	May 29, 2018

Abstract

The present invention relates to a process for determining in vitro the immune status of an individual according to which: (a) a blood sample from the individual is provided, (b) at least two reagents specific to at least two products of expression of at least two target genes are provided; (c) the expression of said at least two target genes is determined, and (d) the expression of said at least two target genes respectively is compared with a reference expression, with a change in the expression of said at least two target genes relative to their reference expression indicating that the individual's immune status has changed, and a correlation between the expression of said at least two target genes with their reference expression indicating that the individual's immune status is normal; as well as a kit for determining said immune status of the individual.

First claim

The invention claimed is:

1. A process for determining in vitro the immune status of an individual having Systemic Inflammatory Response Syndrome comprising:
a. obtaining a blood sample from the individual,
b. contacting the blood sample with at least two reagents specific to at least two products of expression of at least two target genes independently selected from the group consisting of HLA-DR, CD, S100A9, S100A8, ABIN-3, IRAK-M, LY64, CIITA, TNF, IL-10, GBP1, MMP7, CXCL1, CXCL10, COX2, FCN1, TNFAIP6, CXCL7, CXCL5, PID1 and RHOU,
c. measuring expression levels of said at least two target genes in the blood sample, and
d. comparing each of the expression levels of said at least two target genes respectively with an expression level for each of the at least two target genes in healthy individuals,
e. determining that the individual has a deregulated immune response by determining whether at least one component of an immune response of the individual is deregulated,
wherein a difference in the expression level of each of said at least two target genes relative to the expression level for each of the at least two target genes in healthy individuals indicates that at least one component of the immune response of the individual is deregulated, and
f. administering an immunostimulant or immunosuppressor to the individual with a deregulated immune response,
wherein:
the immunostimulant is selected from the group consisting of interleukins, growth factors, interferons, Toll agonists, blocking antibodies, transferrins, and apoptosis-blocking molecules, and
the immunosuppressor is selected from the group consisting of glucocorticoids, cytostatic agents, molecules that act on immunophilins, and cytokines.

2. The process according to claim 1 , wherein at least three reagents that are specific to at least three products of expression of at least three of the target genes are contacted with the blood sample in step b.

3. The process according to claim 1 , wherein at least four reagents that are specific to at least four products of expression of at least four of the target genes are contacted with the blood sample in step b.

4. The process according to claim 1 , wherein at least five reagents that are specific to at least five products of expression of at least five of the target genes are contacted with the blood sample in step b.

5. The process according to claim 1 , wherein the target genes are independently selected from the group consisting of HLA-DRA, S100A9, S100A8, ABIN-3, IRAK-M, LY64, CIITA, TNF-alpha, IL-10, GBP1, MMP7, CXCL1, CXCL10, COX2, FCN1, TNFAIP6, CXCL7, CXCL5, PID1, and RHOU.

6. The process according to claim 1 , wherein the blood sample is a sample taken from an individual who has undergone an immunomodulatory treatment.

7. The process according to claim 1 , further comprising extracting peripheral blood mononuclear cells from the blood sample obtained in step a., and carrying out steps b. to d. on said peripheral blood mononuclear cells.

8. The process according to claim 1 , wherein the reagents specific to the products of expression of the at least two target genes comprise at least two amplification primers specific to said at least two target genes.

9. The process according to claim 1 , wherein the reagents specific to the products of expression of the at least two target genes comprise at least two hybridization probes specific to said at least two target genes.

10. The process according to claim 1 , wherein the reagents specific to the products of expression of the at least two target genes comprise at least two antibodies.

Assignees

• Davin Fanny
• Lepape Alain
• Monneret Guillaume
• Frager Florence
• Biomerieux Sa
• Hospices Civils Lyon

Inventors

• Davin Fanny
• Lepape Alain
• Monneret Guillaume
• Frager Florence

Classifications

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• C40B30/04

  by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q1/6876 Primary

  Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes · CPC title

• G01N33/68

  involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title